SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549

                               FORM 10-KSB

                [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d)
                    OF THE SECURITIES EXCHANGE ACT OF 1934

                  For the Fiscal year December 31, 2000

           [__] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                       OF THE SECURITIES ACT OF 1934

                      Commission File Number 0-18881

                       BRADLEY PHARMACEUTICALS, INC.
                       -----------------------------
              (Name of small business issuer in its charter)

              DELAWARE                      22-2581418
              --------                      ----------
  (State or other jurisdiction of        (I.R.S. Employer
   incorporation or organization)      Identification Number)

    383 Route 46 W., Fairfield, NJ             07004
    ------------------------------             -----
(Address of principal executive offices)     (Zip Code)

   (Registrant's telephone number including area code)    973-882-1505
                                                          ------------

Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
                  Common Stock,  $.01 Par Value Per Share

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for a shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

       Yes   X      No
          -------     -------

Check if there is no disclosure of delinquent filers pursuant to Item 405 of
Regulation S-KSB contained herein, and will not be contained, to the best of
the registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-KSB or any amendment to
this Form 10-KSB. [ ]

State issuer's revenues for its most recent fiscal year:  $18,557,429

The aggregate market value of the Common Stock voting stock held by
nonaffiliates of the Registrant as of March 1, 2001 was approximately
$6,542,000. This amount does not include any value for the Class B Common
Stock, for which there is no established United States public trading market.

As of March 1, 2001, there were outstanding 7,466,146 shares of Common Stock
$.01 par value and 431,522 shares of Class B Common Stock $.01 par value.

Documents incorporated by reference:	None




                                 PART I

Item 1  Business

General

The Company

     We market over-the-counter and prescription pharmaceutical and health
related line currently includes dermatological brands (marketed by our wholly
owned subsidiary, Doak Dermatologics, Inc.) and nutritional, respiratory, and
internal medicine brands (marketed by our Kenwood Therapeutics division).
All our product lines are manufactured and supplied by independent contractors
under our quality control standards and marketed primarily to wholesalers. The
wholesalers, in turn, distribute our products to retail outlets and healthcare
institutions throughout the United States.  We also sell to distributors in
selected international markets.

     Our growth strategy is to make acquisitions, including through
co-marketing and licensing agreements, of established products from major
pharmaceutical organizations that we believe require intensified marketing and
promotional attention.  We believe that significant growth opportunities exist
in this market niche as a result of the divestiture by major pharmaceutical
companies of certain established product lines that are less profitable in
relation to their other products.  As a result, we have acquired, and intend
to continue to acquire, rights to manufacture and market pharmaceutical and
health related products which are effective and for which a demonstrated market
exists, but which are not actively promoted and where the surrounding
competitive environment does not necessarily include major pharmaceutical
companies.

     Our ability to make further product acquisitions will depend, among other
things, on the availability of appropriate acquisition opportunities, the
ability to obtain appropriate financing and our ability to consummate
acquisitions on favorable terms.  There can be no assurance that we will be
able to consummate in a timely way attractive acquisitions on favorable terms.
Therefore, we have and will continue to focus on developing and extending our
existing acquired product lines.

     We were incorporated under the laws of the State of New Jersey in January
1985 and subsequently reincorporated in Delaware in July 1998.  Our principal
executive offices are located at 383 Route 46 West, Fairfield, New Jersey 07004,
telephone number (973) 882-1505.

Material Product Acquisitions
-----------------------------

     We commenced operations in January 1985 and through December 2000 acquired
more than 16 product lines from many leading pharmaceutical companies.  During
this time, we acquired products from Schering-Plough Corporation, Aventis
Healthcare, Inc., American Home Products Corporation, Upsher-Smith Laboratories,
Inc., and Procter & Gamble Pharmaceuticals, Inc.

     In March 1993, we acquired from Tsumura Medical, a division of Tsumura
International, Inc., all technical, proprietary and distribution rights to a
specialized dermal patch product, TRANS-VER-SAL(R) currently used in the
treatment of warts.

     Our most significant acquisition to date was in December 1993, we acquired
from Berlex Laboratories, a subsidiary of Schering AG, all technical,
proprietary rights, including trademarks and registrations to DECONAMINE(R),
a chlorpheniramine maleate/ d-pseudoephedrine HCI prescription product line used
in connection with coughs, colds, and allergies.

     During February 1994, we acquired from the Pharmacia Corporation all U.S.
manufacturing, packaging and proprietary rights, including all trademarks and
registrations to PAMINE(R), a methscopolamine bromide tablet used in connection
with the treatment of peptic ulcers.

     In June 1994, we acquired from Hoffmann-La Roche, Inc. all manufacturing,
packaging, quality control, stability, drug experience, file history, customers
and marketing rights, titles and interests, including all trademarks to
CARMOL(R) 10 and CARMOL(R) 20 nonprescription urea-based moisturizers and
CARMOL(R) HC, a prescription moisturizer containing hydrocortisone, in the
United States and the remaining countries in the Western Hemisphere.

     In May 1996, we acquired the trademark rights to the ACIDMANTLE(R) skin
treatment line from Novartis Pharmaceuticals Corporation, and the exclusive
ACIDMANTLE(R) manufacturing, marketing and distribution rights for the
United States and Puerto Rico.

     In October 1998, we acquired from Procter & Gamble Pharmaceuticals, the
U.S. manufacturing, packaging and proprietary rights, including all trademarks
and registrations to BRONTEX(R), a potent cough reliever.  In consideration, we
agreed to pay Procter & Gamble Pharmaceuticals up to $1,800,000, of which
$600,000 was paid during October 1998.  The remaining balance was paid in
February 2000.

Acquisition of DOAK Subsidiary
------------------------------

     During February 1994, we acquired from Doak Dermatologics' principal
stockholders, a controlling interest in Doak.  The remaining capital stock of
Doak was acquired pursuant to a merger consummated in January 1995.  Total
consideration paid by the Company for Doak was approximately $1.4 million.

Products
--------

     The following is a list of major products, by therapeutic category that we
market and distribute as of March 1, 2001.  All of our products are available
over-the-counter, with the exception of BRONTEX(R), DECONAMINE(R), CARMOL(R) HC,
CARMOL(R) 40, CARMOL(R) SCALP LOTION, CARMOL(R) SCALP TREATMENT KIT,
GLUTOFAC(R)-ZX, GLUTOFAC(R)-MX, LIDAMANTLE(R), PAMINE(R), and TYZINE(R),
each of which is a prescription pharmaceutical.

Dermatological Products                          Uses
-----------------------                          ----

ACIDMANTLE(R) / LIDAMANTLE(R)         Skin acidifier / Rx Topical Anesthetic

CARMOL(R) 10/20/40/HC                 Rx and OTC urea-based family of products
                                      for a variety of dermatological conditions

CARMOL(R) SCALP TREATMENT             Rx and OTC urea-based family of
                                      products for a variety of scalp conditions

FORMULA 405(R)/A-H-A /LE PONT(R)      Variety of topical products for the
                                      skin, hair and nails

TRANS-VER-SAL(R) Wart Remover Kit     Unique dermal patch delivery system for
(6mm, 12mm, 20mm sizes)               wart removal


Nutritional Products                             Uses
--------------------                             ----

GLUTOFAC(R)-ZX/MX                     Rx and OTC vitamin/mineral supplements
                                      for conditions such as diabetes mellitus,
                                      alcoholism, stress, or chronic illness


Internal Medicine Products                       Uses
--------------------------                       ----

PAMINE(R)                             Rx Anticholinergic/antispasmodic


Respiratory Products                             Uses
--------------------                             ----

BRONTEX(R)                            Rx Antitussive/expectorant
(Tablets/Syrup)

DECONAMINE(R) FAMILY                  Rx Antihistamine/decongestant
(SR/Syrup/Tablets)

TYZINE(R)                             Rx Topical nasal decongestant
(Solution/ Nasal Drops)



Product Liability Insurance

     We maintain $3,000,000 of product liability insurance on our products.
This insurance is in addition to required product liability insurance maintained
by the manufacturers of our products.  We believe that this amount of insurance
coverage is adequate and reasonable.  To date no product liability claim has
been made, to our knowledge, against us, and we have no reason to believe that
any claim is pending or threatened.

Manufacturers and Suppliers

     The manufacturing processes and operations of manufacturing facilities for
pharmaceutical products are subject to rigorous regulation, including the need
to comply with the United States Food and Drug Administration's (FDA) and
current good manufacturing practices standards (cGMP's).  All pharmaceutical
products are subject to rigorous regulation by the FDA and state authorities
(as well as comparable agencies in foreign countries), primarily under the
Federal Food Drug and Cosmetic Act and the regulations promulgated thereunder
(along with comparable state laws).  These laws regulate the manufacture,
shipping, storage, sale and use of such products and product samples, including
the cGMP's, and Standard Operating Procedures (SOP's).  The FDA, Federal Trade
Commission and state authorities also regulate the advertising of prescription
and over-the-counter products.  We have not been made aware of any violation
of any such applicable regulatory standards existing through the date of this
10-KSB.

     We generally purchase products from approximately 20 different vendors on
open credit terms, which are generally payable in 30 days.  For the year ended
December 31, 2000, 5 vendors that manufacture and package products for us each
accounted for approximately 13%, 13%, 12%, 11%, and 11% of our cost of
goods sold.  For the year ended December 31, 1999, one vendor that manufactures
and packages products for us accounted for approximately 10% of our cost of
goods sold.  No other vendor, packager or manufacturer accounted for more than
9% of our cost of goods sold for 2000 or 1999.  We currently have no
manufacturing facilities of our own and, accordingly, are dependent upon
maintaining existing relationships with our vendors or establishing new vendors
to supply inventory.  There can be no assurance that we would be able to replace
our current vendors without any disruption to operations.

     With the exception of arrangements relative to BRONTEX(R), CARMOL(R) 10,
CARMOL(R) 20, CARMOL(R) 40, CARMOL(R) SCALP TREATMENT, LIDAMANTLE(R), LUBRIN(R),
PAMINE(R) and TRANS-VER-SAL(R), we do not have any licensing, manufacturing or
other supply agreements with manufacturers or suppliers.

Marketing and Sales

     We have acquired established products and product lines, developed line
extensions for new products and licensed existing technologies.  As a result,
we have concentrated our marketing efforts on the continued promotion of
acquired product lines, line extensions to established customers and the
expansion of distribution to new customers.  Our overall marketing philosophy
is to intensify and enhance the promotion of acquired products and line
extensions throughout the United States and, where feasible, in selected
international markets.

     We market and sell products through full time sales personnel and a network
of distributors and brokers.  Non-prescription products are sold primarily to
drug wholesalers, chain and independent pharmacies, chain and independent food
stores, mass merchandisers, physician supply houses and hospitals.  Prescription
products are sold primarily to wholesalers, retail chains and managed care
providers.  We currently have approximately 1,590 active accounts, of which
there are approximately 200 wholesalers, 890 retail chains and stores, 400
doctors and institutional accounts, 30 government entities and 70 managed care
providers.

     Our DECONAMINE(R) product line (categorized below as respiratory products)
accounted for approximately 12%, 24%, 37%, 45%, and 51%, respectively, of 2000,
1999, 1998, 1997 and 1996 net sales.  Our BRONTEX(R) product line (categorized
below as respiratory products) accounted for 3%, 9% and 7%, respectively, of
2000, 1999 and 1998 net sales, respectively.

     Doak's CARMOL(R) product line accounted for approximately 41%, 22%, 15%,
12%, and 9% of our 2000, 1999, 1998, 1997 and 1996 net sales, respectively.
Changes in the performance of our CARMOL(R) product line, consequently, will
have a material effect on future operations. The TRANS-VER-SAL(R) product line
accounted for approximately 7%, 8%, 8% and 10% of our 2000, 1999, 1998, 1997
net sales, while the ACIDMANTLE(R) product line accounted for approximately 4%,
6%, 6% and 4% of our 2000, 1999, 1998 and 1997 net sales.  Doak's other
products, including Formula 405(R), accounted for approximately 6%, 7%, 9% and
10%, of our 2000, 1999, 1998 and 1997 net sales.  All of Doak's products are
categorized below as dermatologic products.

     Our 2000, 1999, 1998, 1997 and 1996 net sales volume percentages by
category were as follows:

                                        2000  	1999  	1998   1997   1996
                                        --------------------------------


Dermatologic                             59%    43%    40%    40%    32%
Respiratory                              19%    39%    49%    50%    56%
Nutritional                              12%     8%     6%     5%     6%
Personal Hygiene                          1%     2%     3%     4%     4%
Internal Medicine                         9%     8%     2%     1%     2%

     Sales of our DECONAMINE(R) and BRONTEX(R) product lines and other
cough/cold/flu products are primarily concentrated in the fall and winter
months.  Consequently, revenues from these products generally are, and will be,
determined by the severity of the cough/cold/flu season.



     Our principal marketing focus is on the sales of branded pharmaceutical
products. We have a national sales force of over 80 field representatives,
which is comprised of both full and part time employees as well as independent
contractors whose sole focus is the distribution of samples. Our marketing and
sales promotions principally target general/family practitioners, internal
medicine physicians and dermatologists through detailing and sampling to
encourage physicians to prescribe or recommend our products.

     The sales force is supported and supplemented chiefly by telemarketing and
direct mail, and to a lesser extent through advertising in trade publications
and participation at regional and national medical conventions.  We identify
and target physicians through data available from such companies as IMS America,
Ltd. and NDC Health, suppliers of prescriber prescription data. We intend to
seek new markets in which to promote our product lines and will continue
expansion of our field sales force as product growth or product acquisitions
warrant.

     We have made a strategic decision to concentrate selling and marketing
resources on ten principal brands (which represented 90%, 89% and 92% of 2000,
1999 and 1998 net sales, respectively) as follows:

Kenwood Brands                                      Specialty
--------------                                      ---------

BRONTEX(R)                                     General Practitioners,
DECONAMINE(R)                                  Allergists, Pediatricians,
TYZINE(R)                                      Otolaryngologists
ENTSOL(R)

PAMINE(R)                                      Gastroenterologists,
                                               Internal Medicine

GLUTOFAC(R) FAMILY                             General Practitioners


Doak Brands                                         Specialty
-----------                                         ---------

CARMOL(R) FAMILY                               Dermatologists,
TRANS-VER-SAL(R)                               Podiatrists
ACIDMANTLE(R)/LIDAMANTLE(R)

     To facilitate sales of our products internationally (including Puerto
Rico), we have entered into agreements with 33 international pharmaceutical
distributors to provide for distribution and promotion of these products.
Approximately 11%, 9%, 11%, 13% and 11%, respectively, of our 2000, 1999, 1998,
1997 and 1996 net sales were from international business.

     We continue to seek out new distributors and are currently in process of
obtaining market approvals in at least 10 new country markets.  Although we
anticipate to receive the necessary approvals to market our products in these
countries, there can be no assurance that such approvals will be received.

     We have received product registrations and applied for additional product
registrations to distribute products in certain international markets as
follows:


                    OUR INTERNATIONAL MARKETING STATUS

                          CURRENTLY MARKETING


Argentina TRANS-VER-SAL(R) France    TRANS-VER-SAL(R) Qatar     TRANS-VER-SAL(R)

Brunei    ACIDMANTLE(R)    Hong Kong ACIDMANTLE(R)    Saudi     ACIDMANTLE(R)
          BRONTEX(R)                 A-H-A LINE       Arabia    A-H-A LINE
          CARMOL(R)                  CARMOL(R)                  CARMOL(R)
          DECONAMINE(R)              DUADACIN(R)                DOAK(R) TAR
          DOAK(R) TAR                DOAK(R) TAR                FORMULA 405(R)
          DUADACIN(R)                DECONAMINE(R)              SULFOAM(R)
          ENTSOL(R)                  FORMULA 405(R)             SULPHO-LAC(R)
          IRCON(R)                   GLUTOFAC(R)                TERSASEPTIC(R)
          LIDAMANTLE(R)              TERSASEPTIC(R)             TRANS-VER-SAL(R)
          GLUTOFAC(R)                TERSA-TAR(R)
          LUBRIN(R)                                   Singapore ENTSOL(R)
          SULFOAM(R)       Iceland   DOAK(R) TAR                LUBRIN(R)
          SULPHO-LAC(R)              FORMULA 405(R)
          TRANS-VER-SAL(R)           LUBRIN(R)        South     ENTSOL(R)
          TYZINE(R)                  TRANS-VER-SAL(R) Africa    LUBRIN(R)
          PAMINE(R)
                           Israel    LUBRIN(R)        South     LE PONT(R)
Canada    TRANS-VER-SAL(R)                            Korea     IRCON(R)
                           Italy     TRANS-VER-SAL(R)
Chile     TRANS-VER-SAL(R)                            Spain     TAR DISTILLATE
                           Jordan    A-H-A LINE                 TRANS-VER-SAL(R)
Cyprus    A-H-A LINE                 CARMOL(R)
          IPSATOL(R)                 DOAK(R) TAR      Taiwan    A-H-A LINE
          IRCON(R)                   FORMULA 405(R)             FORMULA 405(R)
          KTL(R)                     SULPHO-LAC(R)              LE PONT(R)
          LUBRIN(R)                                             LUBRIN(R)
          TYZINE(R)        Malaysia  LUBRIN(R)                  TRANS-VER-SAL(R)

Denmark   LUBRIN(R)        Mexico    A-H-A LINE       Trinidad  GLUTOFAC(R)-ZX
                                     DOAK(R) TAR      & Tobago  I-L-X(R) B12
Dominican APATATE(R)                 FORMULA 405(R)
Republic  CARMOL(R)                  LUBRIN(R)
          GLUTOFAC(R)                TERSASEPTIC(R)   United    A-H-A LINE
          IRCON(R)                   TRANS-VER-SAL(R) Arab      FORMULA 405(R)
          I-L-X(R) B12                                Emirates  TERSASEPTIC(R)
          KTL(R)           Nether-   LUBRIN(R)
          LUBRIN(R)        lands                      Yemen     A-H-A LINE
                           Pakistan  GLUTOFAC(R)                CARMOL(R)
El        A-H-A LINE                                            DOAK(R) TAR
Salvador  CARMOL(R)        Portugal  TRANS-VER-SAL(R)           FORMULA 405(R)
                                                                TRANS-VER-SAL(R)
Finland   LUBRIN(R)        Puerto    COMPLETE BRADLEY           SULPHO-LAC(R)
                                     LINE                       TERSASEPTIC(R)




Competition

     We compete with other pharmaceutical companies for product and product
line acquisitions and more broadly for the distribution and marketing of
pharmaceutical and consumer products.  These competitors include Dura
Pharmaceuticals, Inc., First Horizon Pharmaceutical, Inc., Forest Laboratories,
Inc., ICN Pharmaceuticals, Inc., King Pharmaceuticals, Inc., Medicis
Pharmaceutical Corporation, Shire Pharmaceuticals, Watson Pharmaceuticals, Inc.
and other companies which also acquire branded pharmaceutical products and
product lines from other pharmaceutical companies. Most of our competitors
possess substantially greater financial, technical, marketing and other
resources than we do.  In addition, we compete for the manufacture of our
products from suppliers who manufacture and supply such products to other
companies, including those competitive with our products.

     Additionally, since our products are generally established and commonly
sold, they are subject to competition from products with similar qualities. Our
pharmaceutical products may be subject to competition from alternate therapies
during the period of patent protection, if applicable, and thereafter from
generic equivalents. The manufacturers of generic products typically do not
bear the related research and development costs or the invested capital in
acquired brands and consequently are able to offer such products at considerably
lower price. There are, however, a number of factors that enable products to
remain profitable once patent protection has ceased. These include the
establishment of a strong brand image with the prescriber or the consumer,
supported by the development of a broader range of alternative formulations
than the manufacturers of generic products typically supply.

Government Regulation

     Our business and our products, including manufacturing processes and
operations of our subcontracted manufacturing facilities, are subject to
extensive and rigorous regulation at both the federal and state levels.  At
the federal level, we and our manufacturers and suppliers are principally
regulated by the FDA as well as by the DEA, the Consumer Product Safety
Commission, the Federal Trade Commission (FTC), the U.S. Department of
Agriculture, Occupational Safety and Health Administration (OSHA) and the U.S.
Environmental Protection Agency (EPA). The FDC Act, the regulations promulgated
thereunder, and other federal and state statutes and regulations, govern, among
other things, the development, testing, manufacture, safety, effectiveness,
labeling, storage, record keeping, approval, advertising and promotion of our
products and those manufactured by and for third parties.  Non-compliance to any
government regulations could have a material adverse effect on our business,
financial condition and results from operations.

     We believe that we have the proper FDA approvals or other marketing
authority for the drugs that we currently market and distribute. Failure to
comply with the statutory and regulatory requirements subjects a manufacturer
or distributor to possible legal or regulatory action, such as suspension of
manufacturing, seizure of product or voluntary recall of a product.  The federal
government has extensive enforcement powers over the activities of
pharmaceutical manufacturers, including authority to withdraw product approvals,
commence actions to seize and prohibit the sale of unapproved or non-complying
products, to halt manufacturing operations that are not in compliance with
cGMPs, and to impose or seek injunctions, voluntary recalls, and civil monetary
and criminal penalties. Such a restriction or prohibition on sales or withdrawal
of approval of products marketed by us could materially adversely affect our
business, financial condition and results of operation.

     While we believe that all of our current pharmaceutical products are
legally marketed under applicable FDA enforcement policies or have received
requisite government approvals for manufacture and sale, such marketing
authority is subject to revocation by the applicable government agencies. In
addition, modifications or enhancements of approved products or changes in
manufacturing locations are in many circumstances subject to additional FDA
approvals which may or may not be received and which may be subject to a lengthy
application process. Our subcontractors are continually subject to inspection
by such governmental agencies and manufacturing operations may be interrupted
or halted in any such facilities if such inspections prove unsatisfactory.

     The distribution of pharmaceutical products is subject to the Prescription
Drug Marketing Act (PDMA), as part of the FDC Act, which regulates such
activities at both the federal and state level. Under the PDMA and its
implementing regulations, states are permitted to require registration of
manufacturers and distributors who provide pharmaceuticals even if such
manufacturers or distributors have no place of business within the state and
states are also permitted to adopt regulations limiting the distribution of
product samples to licensed practitioners.  The PDMA also imposes extensive
licensing, personnel record keeping, packaging, quantity, labeling product
handling and facility storage and security requirements intended to prevent
the sale of pharmaceutical product samples or other diversions.

     U.S. Federal and state governments continue to seek means to reduce costs
of Medicare and Medicaid programs, including placement of restrictions on
reimbursement for, or access to, certain drug products.  As a result, we entered
into a Medicaid Rebate Agreement with the U.S. Government.  Pursuant to the
Rebate Agreement, in order for federal reimbursement to be available for
prescription drugs under state Medicaid plans, we must pay certain statutorily
prescribed rebates on Medicaid purchases.  In most other developed markets in
which our products are marketed and sold, governments exert controls over
pharmaceutical prices either directly or by controlling admission to, or levels
for, reimbursement by government health programs.  The nature of such controls
and their effect on the pharmaceutical industry varies greatly from country to
country.

     We cannot determine what effect changes in regulations or statutes or
legal interpretation, when and if promulgated or enacted, may have on our
business in the future. Changes could, among other things, require changes to
manufacturing methods, expanded or different labeling, the recall, replacement
or discontinuance of certain products, additional record keeping or expanded
documentation of the properties of certain products and scientific
substantiation. Such changes, or new legislation, could have a material
adverse effect on our business, financial condition and results of operations.

     Certain of our pharmaceutical products are sold over-the-counter.  These
products are subject to FDA regulations known as monographs, which specify
permissible active ingredients, labeling and indications.  The monographs are
subject to change.  No assurance can be given that future FDA enforcement or
regulatory decisions or changes to monographs will not hamper our marketing
efforts or render our products unlawful for commercial sale, causing us to
withdraw our products from the marketplace or spend substantial funds
reformulating the products.

     Specifically, our DECONAMINE(R) product line, which currently has
prescription status, falls under these monographs.  Once a final monograph is
issued by the FDA with respect to a product, the product historically can
remain as a prescription product for up to one additional year.  We anticipate
that final monographs for our DECONAMINE(R) product line, thereby converting
the product line from prescription status to over-the-counter status, may
possibly be issued by the FDA at some time in the future.  We currently intend
to continue to market and distribute the DECONAMINE(R) line of products as
prescription products as long as we may lawfully continue to do so.  We are
presently exploring our marketing and distribution strategy relating to the
DECONAMINE(R) product line after final monographs covering these products are
issued, and, as such, we are not currently possible to predict how our
operations and financial condition will be affected, or whether we will have
resources sufficient to aggressively market the DECONAMINE(R) line of products,
if, and when, this product line is converted from prescription status to
over-the-counter status.

     Further, we are required to file an Abbreviated New Drug Application, an
ANDA, with the FDA for our DECONAMINE(R) SR product, which is expected to
maintain the prescription status of this product beyond the final monograph.
The cost of this application is approximately $900,000.  We have entered into
an agreement with Phoenix International to perform clinical studies required
for the issuance of the ANDA.  As of the date of this 10-KSB, we have paid
approximately $350,000 with respect to this project.  The project is being
deferred until regulatory and competitive circumstances warrant completion and
submission to the FDA.  Completion of the research and development project is
subject, however, to us being able to generate sufficient cash flow from
operations to fund the same or obtaining requisite financing from outside
sources, of which there can be no assurance.  Therefore, we cannot at this time
reasonably anticipate the timing of the expenditure of funds for these purposes.
Our inability to further develop and/or file the necessary ANDA for
DECONAMINE(R) SR may have a material adverse effect on our business.

     We currently are the registered holders of one New Drug Application for
PAMINE(R) and two ANDAs for TYZINE(R) and CARMOL(R) HC.  These applications,
approved by the FDA, permit companies to market products either considered by
the FDA to be new drugs or drugs previously approved by the FDA.

     The statutes and regulations that govern our business and activities are
subject to change.  Current political and public interest in pharmaceutical
products may lead to changes in federal and state law, which can affect the
way we do business.  We cannot anticipate what effect, if any, such legislation
may have on our operations.

Patents and Trademarks

     The products currently sold by us, with the exception of TRANS-VER-SAL(R),
ENTSOL(R) Adaptor and CARMOL(R) 40 are not patented and we intend to pursue
patents where it is logical, however, we do not currently intend to apply for
patents for all of our products.  Products with benefits similar to those
marketed by us could easily be developed by other companies.

     The LUBRIN(R) United States patent expired on August 31, 1999 and
TRANS-VER-SAL(R), CARMOL(R) 40, and ENTSOL(R) Adaptor United States patents
expire on October 18, 2005, April 2, 2018, and June 24, 2018, respectively.
Patents maintained for LUBRIN(R) and TRANS-VER-SAL(R) in other countries have
various expiration dates.

     We own all trademarks associated with each of our products including
national and international trademark registrations, or common law rights, for
each of our material products.  No assurance can be given as to the extent or
scope of the trademarks or other proprietary protection secured by us on our
products.  To our knowledge, none of the trademarks owned by us infringe on
any trademarks owned or used by others.

Human Resources

     As of March 1, 2001, we employed 75 full and 41 part-time associates.  We
also maintain active independent contractor relationships with various
individuals with whom we have consulting agreements.  We believe that our
relationship with our associates is good.  None of our associates are subject
to a collective bargaining agreement.

Scientific Advisors

     We have formed a group of scientific advisors having extensive experience
in the areas in which we market our products to advise us in long-range planning
and product development.  The following sets forth information with respect to
our Scientific Advisors:

     Cory A. Golloub, M.D., is a doctor of internal medicine and pediatrics
currently practicing in Montville, New Jersey.  Dr. Golloub received his B.S.
from SUNY Stony Brook and his M.D. from the University of Medicine, Tampico,
Mexico with postgraduate affiliations with SUNY Downstate - Brookdale Hospital
and UMDNJ - New Jersey Medical School.  Dr. Golloub is currently affiliated with
UMDNJ-NJMS, University Hospital and Chilton Memorial Hospital in New Jersey.

     Stephen M. Gross, Ed.D., is Dean of the Arnold and Marie Schwartz College
of Pharmacy & Health Sciences, and of the School of Health Professions, Long
Island University.   Dr. Gross was awarded a B.S. degree in pharmacy in 1960,
and earned his M.A. and Ed.D. degrees in college and university administration
in 1969 and 1975, respectively, from Columbia University.  Dr. Gross' expertise
is in the area of pharmacy administration, where he has authored numerous
articles on a variety of subjects, including cost-effectiveness of drug therapy,
pharmaceutical advertising, and other educational and pharmacy practice topics.
Dr. Gross is also a member of the New York State Board of Pharmacy.

     Michael Kaliner, M.D., is a board certified in Allergy and Immunology.
Dr. Kaliner is currently the Medical Director for the Institute for Asthma and
Allergy and Section Chief for Allergy and Immunology for the Washington Hospital
in Washington, D.C. and Clinical Professor of Medicine at George Washington
University School of Medicine.  He also serves as an officer in several
professional organizations.  He previously was the President of the American
Academy of Allergy, Asthma and Immunology and Chairman of the Board of Allergy
and Immunology.  He held offices with the World Allergy Organization: Treasurer,
Second Vice President and Chairman of the 18th Congress.  He has also authored
more than 425 articles and books.  Dr. Kaliner received his B.S. and M.D. from
the University of Maryland.

     Lewis H. Kaminester, M.D., F.A.A.D., F.A.C.P., is a dermatologist
practicing in North Palm Beach for the past 25 years. Dr. Kaminester graduated
Franklin and Marshall College with Honors in Biology and as member of Phi Beta
Kappa.  He graduated from University of Pennsylvania School of Medicine, where
he was also a dermatology resident.  He is on the clinical staff at University
of Miami School of Medicine, Department of Dermatology and Dermatological
Surgery.

     Richard H. Mann, D.P.M. is a doctor of podiatric medicine, board-certified
in foot and ankle surgery, microscopic laser surgery of the foot and is a
Fellow of the Academy of Ambulatory Foot Surgeons and American College of Foot
Surgeons.  Dr. Mann received his B.A. from Queens College of the City University
of New York and his D.P.M. from the New York College of Podiatric Medicine. Dr.
Mann has developed several new pharmaceutical products in a wide variety of
medical areas.

     David Parsons, M.D. is a board certified ear, nose and throat surgeon, and
a Fellow of the American College of Surgeons.  He is a recognized international
authority on paranasal sinus disease and has written an authoritative textbook
on sinus care.  Dr. Parsons enjoyed a 26-year Air Force career which included
serving as the Consultant to the Surgeon General for Head & Neck Surgery, Vice
Chairman of the Department of Otolaryngology, Wilford Hall USAF Medical Center,
and Clinical Professor of Otolaryngology/Head & Neck Surgery at the University
of Texas-San Antonio and at the University of Colorado.  Most recently, he was
Professor of Surgery and Pediatrics at the University of Missouri-Columbia. Dr.
Parsons received his M.D. degree from the University of Texas-Houston, and is
now in private practice of Otolaryngology.

     Alan R. Shalita, M.D. is a board certified dermatologist and currently
Professor and Chairman of the State University of New York Health Science Center
at Brooklyn. Dr. Shalita received his B.S. from University of Brussels, Belgium
and M.D. from Bowman Gray School of Medicine. Dr. Shalita is also licensed in
New Jersey, North Carolina, California and Florida.

     Keyoumars Soltani, M.D. is currently Professor of Dermatology in the
Department of Medicine at the University of Chicago. Dr. Soltani completed his
residency at Temple University Skin & Cancer Hospital of Philadelphia.  Dr.
Soltani is a member of numerous scientific professional societies. He is the
author/co-author of over 200 publications, especially in the fields of
immunodermatology, cutaneous manifestations of systemic diseases and
dermatopharmacology.

     Mitchell J. Spirt, M.D. is a doctor of internal medicine currently on
faculty as Assistant Clinical Professor of Medicine at the UCLA School of
Medicine, California.  Dr. Spirt received his B.S. from University of New York
at Binghamton and received his M.D. from Mount Sinai Medical Center in New
York. Dr. Spirt performed his internship and residency at Mount Sinai Medical
Center, New York and a Fellow at the University of California at Los Angeles
(UCLA).

     Gerald N. Wachs, M.D. is a doctor of dermatology currently practicing in
Millburn, New Jersey.  Dr. Wachs received his B.S. and M.D. from the University
of Illinois.  Dr. Wachs is currently affiliated with St. Barnabas Hospital and
Overlook Hospital in New Jersey and is a consulting dermatologist for the New
Jersey Nets and New Jersey Devils.


Item 2. Properties

     We lease 14,100 square feet of office and warehouse space at 383 Route 46
West, Fairfield, New Jersey, expiring on February 1, 2003 with Daniel Glassman,
Chairman and President, and his spouse Iris Glassman, Treasurer.   Rent expense,
including our proportionate share of real estate taxes, was approximately
$225,000 and $224,000 in 2000 and 1999, respectively.

     During 1999, our subsidiary, Doak, closed its former 11,000 square foot
manufacturing facility, owned by the former principal stockholders of Doak, and
an independent satellite warehouse in Westbury, NY.  Our related 1999 rent
expense for this manufacturing facility totaled $5,000.  In conjunction with
the closing of Doak's manufacturing facility, we did not renew this lease.

     During 2000 and 1999, we rented 760 square feet of office space in
Chicago, Illinois at cost of $18,000 and $17,000, respectively, per annum.

     During 1999, we entered into a two year, 6,000 ft. lease, with a one year
renewal option, for warehouse space at 33 Route 46 West, Fairfield, New Jersey
primarily for the storage of promotional items and pharmaceutical samples.
Rent expense, which includes common area maintenance and real estate taxes, was
$50,000 and $45,000 in 2000 and 1999, respectively.

     We believe that the aforementioned facilities are sufficient to meet our
current requirements; however, we anticipate that as we grow, we may require
additional facilities.

     We also have a distribution arrangement with a third party public
warehouse located in Tennessee to warehouse and distribute substantially all
of our products.  This arrangement provides that we will be billed based on
invoiced sales of the products distributed by such party, plus an additional
charge per order.

Item 3.	Legal Proceedings

     We are involved in legal proceedings of various types in the ordinary
course of business.  While any such litigation to which we are a party contains
an element of uncertainty, we presently believe that the outcome of each such
proceeding or claim which is pending or known to be threatened, or all of them
combined, will not have a material adverse effect on our consolidated financial
position or results of operations.

Item 4.	Submission of Matters to a Vote of Security Holders

     No issues were submitted to a vote of the security holders during the
fourth quarter of 2000.

Item 5.	Market for Common Equity and Related Stockholder Matters.

     Shares of our common stock are traded on The Nasdaq Stock MarketTM under
the trading symbol "BPRX".  Our Class B common stock is not publicly traded.


     The following table sets forth the high and low sales prices for shares
of our common stock on The Nasdaq Stock MarketTM for the periods indicated.



                                          High Sale          Low Sale
                                          ---------          --------

Fiscal year ended December 31, 2000
         First quarter                     $ 4.31             $ 1.06
         Second quarter                      2.50               0.97
         Third quarter                       1.50               1.13
         Fourth quarter                      2.00               1.00


Fiscal year ended December 31, 1999
         First quarter                     $ 1.56             $ 1.00
         Second quarter                      1.63               1.03
         Third quarter                       1.50               1.03
         Fourth quarter                      1.38               1.00

     On March 1, 2001 the last sale price for our shares of common stock as
reported by the Nasdaq National Market was $2.31 per share.  At March 1, 2001,
there were approximately 290 registered holders of record of shares of common
stock.  Based on information available, we believe that there are approximately
2,900 beneficial holders of shares of common stock held in "street" or other
nominee name at such date.

     We have not paid any dividends on our common stock since organization in
January 1985.  We anticipate in the foreseeable future, any earnings will be
retained for use in our business and, accordingly, we do not anticipate the
payment of cash dividends.

     We have authorized an aggregate of 900,000 shares of Class B common stock,
$.01 par value per share, of which 431,552 shares were issued and outstanding
at March 1, 2001.  The Class B common stock is not publicly traded.  The rights,
preferences and limitations of common stock and Class B common stock are equal
and identical in all respects, except that the holders of the Class B common
stock are entitled to elect a majority of our directors and each share of common
stock entitles the holder thereof to one vote upon any and all matters submitted
to the stockholders of the Corporation for a vote, and each share of Class B
common stock entitles the holder thereof to five votes upon certain matters
(other than the election of directors) submitted to the stockholders of the
Corporation for a vote.

     At March 1, 2001, there were outstanding 7,466,146 of common stock.



Item 6.	Management's Discussion and Analysis of Financial Condition and Results
        of Operations

     The following discussions should be read in conjunction with the financial
statements and notes thereto included elsewhere in the Annual Report.
Historical results and percentage relationships set forth in the statement of
income, including trends that might appear, are not necessarily indicative of
future operations.

Overview

     We market over-the-counter and prescription pharmaceutical and health
related products.  Our product line currently includes dermatological brands
(marketed by our wholly owned subsidiary, Doak Dermatologics, Inc.) and
nutritional, respiratory, and internal medicine brands (marketed by our Kenwood
Therapeutics division).  All our product lines are manufactured and supplied
by independent contractors under our quality control standards and marketed
primarily to wholesalers. The wholesalers, in turn, distribute our products to
retail outlets and healthcare institutions throughout the United States.  We
also sell to distributors in selected international markets.

     Our growth strategy is to make acquisitions, including through co-marketing
and licensing agreements, of established products from major pharmaceutical
organizations that we believe require intensified marketing and promotional
attention.  We believe that significant growth opportunities exist in this
market niche as a result of the divestiture by major pharmaceutical companies
of certain established product lines that are less profitable in relation to
their other products.  As a result, we have acquired, and intend to continue
to acquire, rights to manufacture and market pharmaceutical and health related
products which are effective and for which a demonstrated market exists, but
which are not actively promoted and where the surrounding competitive
environment does not necessarily include major pharmaceutical companies.

Results of Operations

     Net Sales (net of all adjustments to sales) for 2000 was $18,557,000,
representing a decrease of $293,000, or approximately 2%, from 1999.  This
decrease primarily reflects declines resulting from Kenwood Therapeutics
respiratory products, mostly DECONAMINE(R) and BRONTEX(R), which was partially
offset by gains resulting from Doak Dermatologics' product CARMOL(R) 40, and
Kenwood Therapeutics' products PAMINE(R) and GLUTOFAC(R)-ZX.  The decline was
also partially offset by new product sales of CARMOL(R) SCALP TREATMENT,
CARMOL(R)40 7oz, and GLUTOFAC(R)-MX of approximately $2,400,000.  The increase
in same product sales of CARMOL(R) 40, PAMINE(R) and GLUTOFAC(R)-ZX was
primarily due to greater promotional attention, the utilization of market
research data to ensure product messages are received by the most potentially
productive audiences, and the offering of slight discounts to wholesalers to
encourage stocking. The sales decline of DECONAMINE(R) and BRONTEX(R) was
primarily attributable to an increase in generic competition and/or therapeutic
substitution, formulary restrictions, and the launch of new competitive
products.  Our analysis of the trend in actual chargebacks and rebates resulted
in an decrease in the percentage used to adjust gross sales to net sales for
1999, resulting in increased net sales and profits of $464,000.  Any future
changes of this percentage will reflect continuing and future analysis of this
trend.  There is no assurance that this trend will continue.

     Cost of Sales for 2000 was $4,272,000, representing a decrease from 1999
of $811,000.  Our gross profit margin for 2000 was 77% as compared to 73%
during 1999.  The improvement in the gross profit margin reflects a change in
our sales mix with greater sales of prescription products that historically
carry a higher gross profit percentage.  The change in the sales mix
represented an increase in prescription products of PAMINE(R), CARMOL(R) 40,
and GLUTOFAC(R)-ZX.  In addition, we benefited from cost savings due to
outsourcing to more cost efficient vendors.

     Selling, General and Administrative Expenses for 2000 was $11,647,000,
representing an increase of $174,000 over 1999.  The increase in selling,
general and administrative expenses was primarily due to the EVA(R) Financial
Management System and its related variable compensation.  The EVA(R) Financial
Management System, which is based upon attaining certain corporate goals and
annual performances, resulted in an increase in compensation expense of
$499,000 versus 1999, which was partially offset due to a change in strategic
focus from promoting respiratory products to even greater attention given to
dermatology, nutritional, and internal medicine products.  In particular, we
benefited in decreased shipping costs associated BRONTEX(R) sample fulfillment.

     Depreciation and Amortization Expenses for 2000 was $955,000, representing
a decrease of $183,000 as compared to 1999.  The decrease for 2000 was
principally due to the reduction in amortization of the intangible asset
DECONAMINE(R), as result of the impairment write-off taken in the First Quarter
2000.

     Interest Expense, Net for 2000 was $248,000, representing an increase of
$13,000 from 1999.  The increase was principally due to an increase in interest
rates on the revolving asset-based credit facility and the acquisition note.

     Loss Due to Impairment of Asset for 2000 was $3,897,000.  We recorded an
impairment loss relating to the DECONAMINE(R) trademark.  As a result of our
strategic review process of our product lines and related intangible assets,
we determined that an event or circumstance occurred.  We changed our future
sales forecast for the product during April 2000 after it became apparent that
significant marketing attention during the Fourth Quarter 1999 had minimal
impact on the product's sales. Consequently, the fair value of the DECONAMINE(R)
trademark was calculated on the basis of discounted estimated future cash
flows and resulted in a non-cash charge of $3,897,000. This charge, which has
been recorded in the consolidated statement of income, had no impact on the
Company's cash flow.  No impairment loss was recorded for 1999.

     Income Tax Benefit for 2000 was $398,000, in comparison to an income tax
expense of $360,000 for 1999 or an improvement of $758,000.  The improvement
was principally due to a reduction of the valuation allowance against our
deferred tax assets.  In 1999, deferred tax assets were fully reserved.

     Net Loss for 2000 was $2,063,000 as compared to net income of $561,000 in
1999, representing a decrease of $2,624,000.  The decrease was principally due
to the loss due to impairment of asset of $3,897,000, which was partially offset
by an increase in gross profit, a decrease in depreciation and amortization and
the recording of an income tax benefit.

     Net loss for Kenwood Therapeutics for 2000 was $4,031,000, representing a
decrease of $3,782,000 from 1999.  The decrease was principally due to a
decrease in net sales of $3,023,000 and the loss due to impairment of asset.
The products DECONAMINE(R) and BRONTEX(R) primarily contributed to the decrease
in net sales, which was partially offset by an increase in PAMINE(R) and
GLUTOFAC(R)-ZX.

     Net income for Doak Dermatologics for 2000 was $1,968,000, representing
an increase of $1,158,000 from 1999.  The increase was principally due to an
increase in net sales of $2,730,000 and an increase in the gross profit margin
from 71% to 82%. The same product sales of CARMOL(R) 40 and new product sales
of CARMOL(R) SCALP TREATMENT and CARMOL(R)40 7oz primarily contributed to the
increase in net sales and gross profit margin.

Liquidity and Capital Resources

     Our liquidity requirements arise from debt service, working capital
requirements and funding of acquisitions.  We have historically met these cash
requirements through cash from operations, proceeds from our line of credit,
borrowings for product acquisitions and the issuance of common stock.

     On December 31, 2000, we had working capital of $3,412,000, an increase of
$2,675,000 over the December 31, 1999 working capital of $737,000. The increase
in our working capital position at December 31, 2000 was primarily due to an
increase in accounts receivable, a reduction in the current maturities of
long-term debt, a reduction in accounts payable, a reduction in borrowings on
the revolving credit, a reduction in income taxes payable and the recording of
a deferred tax asset, which was partially offset due to reductions in inventory,
a reduction in prepaid samples and materials, and an increase in accrued
expenses.

     Our cash and cash equivalents were $453,000 and $386,000 at December 31,
2000 and 1999, respectively. Cash provided by operating activities for the year
ended December 31, 2000 was $1,962,000.  The sources of cash primarily resulted
from (i) a net loss of $2,063,000, offset by non-cash charges for depreciation
and amortization of $955,000, compensation for consulting services of $19,000
and loss due to impairment of asset of $3,897,000; (ii) an increase in allowance
for doubtful accounts of $50,000; (iii) an increase in deferred tax assets of
$1,043,000; (iv) an increase in the inventory provision of $430,000 due to slow
moving inventory;  (v) an increase in accounts receivable of $950,000, primarily
due to increased sales during December 2000, which was prompted by a
pre-announced price increase;  (vi) a decrease in inventory and prepaid samples
and materials of $435,000, primarily due to usage of our inventory stocking
from the Year 2000; (vii) a decrease in prepaid expenses and other of $93,000;
(viii) a decrease in accounts payable of $277,000; (ix) an increase in accrued
expenses of $507,000, primarily due to an increase in accrued bonuses for the
EVA(R) Financial Management System; and (x) a decrease in income tax payable of
$91,000.  Cash used in operating activities for the year ended December 31, 1999
was $21,000.  This use of net cash was primarily the result of an increase in
accounts receivable and inventory and prepaid samples and materials partially
offset by increases in accounts payable, accrued expenses, and income taxes
payable plus net income and non-cash charges of depreciation and amortization.

     Cash used in investing activities for the year ended December 31, 2000
and 1999 were $72,000 and $63,000, respectively.  The investment in 2000 was
primarily for the purchase of property and equipment.  The investment in 1999
consisted of investment in trademarks and other intangible assets of $92,000,
purchases of property and equipment of $60,000, and offsetting proceeds from
sale of fixed assets of $89,000.

     Cash used in financing activities for the year ended December 31, 2000
and 1999 were $1,823,000 and $948,000, respectively.  The financing activities
for 2000 consisted primarily of (i) a payment of long-term debt of $1,504,000;
(ii) proceeds from the acquisition note with LaSalle Business Credit, Inc. of
$1,161,000; (iii) net repayments of the revolving credit line of $1,543,000;
(iv) purchases of treasury stock of $32,000; and (v) distributions of treasury
stock of $92,000 due to funding the 401(k) Plan contributions.  The financing
activities for 1999 consisted primarily of (i) a payment of long-term debt of
$111,000; (ii) net repayments of the revolving credit line of $275,000;
(iii) purchase of treasury stock of $570,000; and (iv) distributions of treasury
stock of $23,000 due to funding the 401(k) Plan contributions.

     On April 7, 1999, we entered into a loan agreement with LaSalle Business
Credit, Inc. that is comprised of a $5 million revolving asset-based credit
facility and a $2.5 million acquisition note for future product acquisitions.
In order to close this new loan agreement with LaSalle, we paid in full the
outstanding loan balance and early termination penalties to The CIT Group/Credit
Finance, Inc. of approximately $1.6 million, using a portion of the availability
from the new revolving credit facility.  Advances under the new revolving credit
facility are calculated pursuant to a formula, which is based on our eligible
accounts receivable and inventory levels.  Advances under the $2.5 million
acquisition note are pursuant to our finding a potential acquisition and
receiving LaSalle's final approval.  At the execution date, this new loan
agreement had an initial term of three years, required an annual fee, and was
subject to an unused credit line percentage fee of one quarter of one percent
(.25%).  Interest accrued on amounts outstanding under this new loan agreement
at the rate equal to the prime rate of interest, announced from time to time,
by LaSalle National Bank plus 1% for the revolving credit facility and plus 2%
for the amount outstanding for the acquisition note.  Our obligations under the
new loan have been collateralized by our grant to LaSalle of a lien upon, and
the pledge of a security interest to our prior lien with CIT, which consists
of substantially all of our assets.

     The loan agreement with LaSalle includes various restrictive covenants
prohibiting us with certain limited exceptions, from, among other things,
incurring additional indebtedness and paying dividends, substantial asset sales
and certain other payments.  The loan agreement also contains financial
covenants including net worth, minimum net loss, interest coverage ratio, debt
service ratio, and earnings before interest, taxes, depreciation, and
amortization ("EBITDA").

     On February 7, 2000, we borrowed $1,161,000 from the acquisition note in
order to satisfy the note payable that was in connection with the acquisition
of BRONTEX(R).

     On June 19, 2000, LaSalle amended the Loan Agreement by reducing future
funding through the use of the acquisition note by $1 million, decreasing the
revolving asset-based credit facility by $1.5 million, increasing the interest
rate by 1/2% for the acquisition note, increasing the interest rate by 1/2% for
the revolving asset-based credit facility, and altered some covenants to more
favorable terms.

     The amended Loan Agreement is comprised of a $3.5 million revolving
asset-based credit facility and a $1.5 million acquisition note.  Interest now
accrues on amounts outstanding under this Loan Agreement at the rate equal to
the prime rate of interest, announced from time to time, by LaSalle National
Bank plus 1 1/2% for the revolving credit facility (11% as of December 31, 2000)
and plus 2 1/2% for the amount outstanding for the acquisition note (12% as of
December 31, 2000).

     We had $578,000 and $919,000 in borrowings issued under the revolving
asset-based line of credit and the acquisition note at December 31, 2000,
respectively, with a remaining availability pursuant to a borrowing base of
$2,922,000 from the revolving line of credit and $411,000 from the acquisition
note.

     Management believes that our cash and cash equivalents and cash generated
from operations will be adequate to fund our current working capital
requirements for at least the next 12 months.  However, in the event that we
make significant acquisitions in the future, we may be required to raise
additional funds through additional borrowings or the issuance of debt or
equity securities.

Impact of Inflation

     We have experienced only moderate price increases under our agreements
with third-party manufactures as a result of raw material and labor price
increases.  We have passed these price increases along to our customers.
However, there can be no assurance that possible future inflation would not
impact our operations.

Seasonality

     Sales of certain products, such as cough and cold products, increase
between October and March due to the cold and flu season.  We expect the impact
of seasonality to decrease as we acquire or obtain licenses for products that
treat chronic conditions.  However, we anticipate that the seasonality may
continue to affect sales for the foreseeable future.

Recent Accounting Pronouncements

     In June 2000, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standard No. 138, "Accounting for Certain Derivative
Instruments and Certain Hedging Activities, an Amendment of FASB Statement
No. 133." SFAS No. 138 was issued to address a limited number of issues causing
implementation difficulties for entities that apply SFAS No. 133, "Accounting
for Derivative Instruments and Hedging Activities," issued in June 1998. SFAS
No. 133 and SFAS No. 138 require that all derivatives be measured at fair value
and recognized as assets or liabilities on the balance sheet. Changes in the
fair value of derivatives should be recognized in either net income/(loss) or
other comprehensive income/(loss), depending on the designated purpose of the
derivative. The Company is required to and will adopt SFAS No. 133 and SFAS
No. 138 in the first quarter of 2001. Based on our current activities, we do
not believe that adoption of these pronouncements will have a material impact
on our results of operations, cash flows or financial position.

Market Risk

     Our operating results and cash flows are subject to fluctuations from
changes in foreign currency exchange rates and interest rates.  Our purchases
of ENTSOL(R) Spray are made in French Francs.  We expect to make purchases
several times per year.  While the effect of foreign currency translations has
not been material to our results of operations to date, currency translations
on import purchases could be adversely affected in the future by the
relationship of the U.S. dollar with foreign currencies.  In addition, foreign
currency fluctuations can have an adverse affect upon exports, even though we
recognize sales to international distributors in U.S. dollars.  Foreign currency
fluctuations can directly affect the marketability of our products in
international markets.

     To the extent that we borrow under our credit facility with LaSalle Bank,
we will experience market risk with respect to changes on the general level of
the interest rates and its effect upon our interest expense.  Borrowings under
our credit facility with LaSalle bear interest at variable rates.  Because
such rates are variable, an increase in interest rates will result in additional
interest expense and a reduction in interest rates will result in reduced
interest expense.

     Stock prices of emerging growth pharmaceutical and micro-cap companies,
such as us, are subject to significant fluctuations.  Our stock price may be
affected by a variety of factors that could cause the price to fluctuate,
perhaps, substantially, including: announcements of developments related to the
our business; quarterly fluctuations in our actual or anticipated operating
results; general conditions in the pharmaceutical and health care industries;
new products or product enhancements by us or our competitors; developments in
patents or other intellectual property rights and litigation; and developments
in our relationships with our customers and suppliers.  In addition, in recent
years the stock market in general and the market for shares for small
capitalization and emerging growth pharmaceutical companies in particular, have
experienced extreme price fluctuations which may or may not been related to the
operating performance of affected companies.  Any such fluctuations in the
future could adversely affect the market price of our common stock.  There can
be no assurance that the market price of our common stock will not decline.

Forward-Looking Statements

     This document may contain forward-looking statements that reflect our
current view of future events and operations.  These forward-looking statements
are based on assumptions and external factors, including assumptions relating
to regulatory action, capital requirements and competing products. Any changes
in such assumptions or external factors could produce significantly different
results.

Item 7.  Financial Statements and Supplementary Data

     The financial statements required by Item 7 are appended to this Form
10-KSB.

Item 8.  Changes in and Disagreements with Accountants on Accounting and
          Financial Disclosure

     None



Item 9.  Directors and Executive Officers

     The directors and executive officers of the Company are as follows:

                                        Age               Position(s)
                                        ---               -----------

Daniel Glassman                          58      Chairman of the Board,
                                                 President and Chief Executive
                                                 Officer

Iris S. Glassman                         58      Treasurer and Director

Philip W. McGinn, Ph.D.                  75      Director

Seymour I. Schlager, M.D.                51      Director

Bruce W. Simpson                         59      Secretary and Director

Alan G. Wolin, Ph.D.                     68      Director




Dileep Bhagwat, Ph.D.                    49      Vice President, Chief
                                                 Scientific Officer

Robert Corbo                             46      Vice President, Quality Control
                                                 and Assurance

Robert Dubin                             52      Sr. Vice President, Sales and
                                                 Contract Administration

Bradley Glassman                         27      Vice President, Marketing

Gene L. Goldberg                         62      Sr. Vice President, Marketing
                                                 and Business Planning

R. Brent Lenczycki                       29      Vice President, Chief Financial
                                                 Officer


     Daniel Glassman is our founder and has served as our Chief Executive
Officer since inception in January 1985.  Mr. Glassman has also served as our
Chairman of the Board since January 1985.  Mr. Glassman has also served as our
President since February 1991.  Mr. Glassman, a registered pharmacist, is also
Chairman of the Board of Banyan Communications Group, Inc., a communications
company founded by Mr. Glassman.  Mr. Glassman has had a 35 year career in the
pharmaceutical industry, including executive managerial positions with companies
and major specialty advertising agencies serving the largest pharmaceutical
companies.  Mr. Glassman is also Chairman of the Board, President and Chief
Executive Officer of Doak, Bradley Pharmaceuticals (Canada), Inc. and Bradley
Pharmaceuticals, Overseas, Ltd., Inc., each our subsidiary.  In 1995, Mr.
Glassman was awarded the Ernst & Young LLP Entrepreneur of the Year in
New Jersey.

     Iris S. Glassman has served as our Treasurer since its inception in 1985.
Mrs. Glassman, the spouse of Mr. Daniel Glassman, has also served as one of our
directors from January 1985.  Mrs. Glassman has over 20 years of diversified
administrative and financial management experience, including serving in the
capacity of Secretary of Banyan.

     Philip W. McGinn, Jr., Ph.D. has served as one of our directors since
December 1996.  Since 1984, Dr. McGinn has also served as President of Worldwide
Marketing and Translation Services, Inc., a New Jersey based company providing
consulting services in new product and company acquisitions, marketing, market
analysis, promotional planning, sales training, management development and
business, educational and translation services. Dr. McGinn also served as
Associate Dean, School of Health Professions, Long Island University from 1990
to 1996.

     Seymour I. Schlager, M.D., J.D. has served as one of our directors since
July 1998.  From 1989 to 1991, Dr. Schlager served as Venture Head of the
AIDS/Antiviral Pharmaceutical product development group of Abbott
Laboratories.  In 1997, Dr. Schlager received a Juris Doctorate, cum laude, from
William Howard Taft University School of Law complementing his M.D. from the
University of Miami School of Medicine.  Currently, Dr. Schlager is Vice
President of Medical Affairs for Becton Dickinson Medical Systems.

     Bruce W. Simpson, has served as our Secretary since June 2000 and one of
our directors since January 2000.  Mr. Simpson currently heads a private
consulting firm that specializes in marketing and business development in the
healthcare industry.  Prior to founding his own healthcare consulting firm,
Mr. Simpson was President of Genpharm, Inc. and President and CEO of Medeva
Pharmaceuticals.  Previous to those positions, Mr. Simpson served in the
capacity of Vice President of Sales & Marketing, and Executive Vice President
of Ethical Pharmaceuticals for Fisons Corporation. Mr. Simpson received a M.B.A.
from the University of Hartford.  He has been affiliated with the American
Academy of Allergy and was a Board Member of Menley & James Pharmaceuticals.

     Alan G. Wolin, Ph.D., has served as one of our directors since May 1997.
Since 1988, Dr. Wolin has served as an independent consultant to various
companies in the food, drug and cosmetic industries.  Prior to 1987, Dr. Wolin
served M&M/Mars, the world's largest candy company, in various capacities,
including Director of Consumer Quality Assurance and Quality Coordination.  In
his capacity as Director of Consumer Quality Assurance and Quality Coordination,
Dr. Wolin was responsible for ensuring consumer quality and public health issues
relating to M&M/Mars' products.

     Dileep Bhagwat, Ph.D. has served as our Vice President and Chief Scientific
Officer since September 1999.  Previously, Dr. Bhagwat was employed at Penwest
Pharmaceuticals, as Vice President, Scientific Development and Regulatory
Affairs.  Prior to that appointment, Dr. Bhagwat was Assistant Director of
Pharmaceutical Development at Purdue Frederick Research Center.  Dr. Bhagwat
holds a M.S. and Ph.D. in Industrial Pharmacy from St. John's University and
a M.B.A. from Pace University.

     Robert Corbo has served as our Vice President Quality Assurance since 1997
and as Quality Assurance/Control Director since March 1993.  From 1989 to 1993,
Mr. Corbo served as Quality Assurance/Control manager for Par Pharmaceuticals,
a New York based generic pharmaceutical manufacturer.

     Robert Dubin, R.Ph. has served as our Senior Vice President, Sales and
Contract Administration since 1997.  Prior experience includes a manufacturer
of food products for a major U.S. food distributor and a Consultant Pharmacist
position for a major group of nursing homes in the Chicago area; also
owner/operator of 15 pharmacies and health clinics.

     Bradley Glassman has served as our Vice President, Marketing since April
2000, Director of Corporate Development since May 1998 and as a Corporate
Development Analyst since May 1996.  In 1996, Mr. Glassman received a Masters
of Business Administration from Tulane University.

     Gene L. Goldberg has served as our Senior Vice President, Marketing and
Business Planning since January 1997. Formerly Executive Vice President of
Daniel Glassman Advertising and Vice President and Account Supervisor for
William Douglas McAdams.  Also garnered experience as Senior Product Manager
for USV Pharmaceutical Corporation, division of Revlon Healthcare Group;
Project Director in Market Research at McAdams, Geigy Pharmaceutical Company
and Lea-Mendota Research Group.

     R. Brent Lenczycki, CPA, has served as Vice President and Chief Financial
Officer since January 2001. Since joining Bradley Pharmaceuticals in 1998,
Mr. Lenczycki has held the positions of Manager of Finance and Purchasing,
Director of Finance and Vice President, Finance.  Previously, Mr. Lenczycki held
positions in public accounting at Arthur Andersen LLP in Philadelphia, PA, and
as an internal auditor for Harrah's Hotel and Casino in Atlantic City,
New Jersey.  Mr. Lenczycki holds an MBA concentrated in Finance.



     Our directors are scheduled to hold office until the next Annual Meeting
of Stockholders and until their respective successors shall have been duly
elected and qualified.


Item 10. Executive Compensation

                        Summary Compensation Table

     The following table shows all of our cash compensation paid, as well as
certain other compensation paid or accrued during the years ended
December 31, 2000, 1999 and 1998, to Daniel Glassman, President and Chief
Executive Officer, Robert Dubin, Senior Vice President of Sales and Contract
Administration, Gene L. Goldberg, Senior Vice President of Marketing and
Business Planning and Maurice Woosley, former President, Bradley International.
No other of our executive officers earned total annual salary and bonus for
2000 in all capacities in which such person served was in excess of $100,000.
There were no restricted stock awards, long-term incentive plan payouts or
other compensation paid during 2000 to the executive officers named in the
following table except as set forth below:


                                                                   Long-Term
                                                                  Compensation
                                 Annual Compensation                 Awards
                                 -------------------                 ------


Name and Principal Position    Year    Salary     Bonus    Securities Underlying
---------------------------    ----    ------     -----    ---------------------
                                                                Options(1)
                                                                ----------

Daniel Glassman                2000   $192,500    $6,400        359,589(4)
  President and                1999   $196,700   $18,400        300,000(3)
  Chief Executive Officer      1998   $164,800      -0-          55,000(2)


Dileep Bhagwat, Ph.D.          2000   $115,100    $1,400           -0-
  Vice President and           1999    $35,000      -0-          12,000(5)
  Chief Scientific Officer     1998      N/A        N/A            N/A


Robert Dubin                   2000   $140,300    $2,700           -0-
  Senior Vice President        1999   $127,900    $7,600           -0-
  of Sales and Contract        1998   $115,400      -0-           6,000
  Administration


Gene L. Goldberg               2000   $149,200    $2,800           -0-
  Senior Vice President        1999   $141,200    $8,100           -0-
  Marketing and Business       1998   $135,400      -0-            -0-
  Planning



(1) All of these options are exercisable into shares of common stock.

(2) Of these shares, 25,000 underlie options granted on January 27, 1998 to
    replace a like number of options previously granted to Mr. Glassman, which
    expired by their terms.  These options are exercisable after January 27,
    1999, 2000, 2001 for 8,333, 8,333 and 8,333 shares, respectively, at an
    exercise price of $1.99 per share, 110% of the fair market value for shares
    of common stock on the date of the grant.  These options will expire on
    January 26, 2003.  The remaining 30,000 shares underlie options granted on
    June 9, 1998 to replace like number of options previously granted to Mr.
    Glassman which expired by their terms.  These options are exercisable
    anytime prior to June 8, 2003 at an exercise price of $2.07 per share,
    110% of the fair market value for shares of common stock on the date of
    grant.


(3) Of these shares, 150,000 underlie options granted on January 21, 1999 to
    replace a like number of options previously granted to Mr. Glassman, which
    expired by their terms.  These options are exercisable after January 21,
    1999, 2000, 2001 for 50,000, 50,000 and 50,000 shares, respectively, at an
    exercise price of $1.44 per share, 110% of the fair market value for shares
    of common stock on the date of the grant.  These options will expire on
    January 20, 2004.  The remaining 150,000 shares underlie options granted
    on October 26, 1999 to replace like number of options previously granted
    to Mr. Glassman, which expired by their terms.  These options are
    exercisable after October 26, 2000, 2001, 2002 for 50,000, 50,000 and
    50,000 shares, respectively, at an exercise price of $1.17 per share, 110%
    of the fair market value for shares of common stock on the date of grant.
    These options will expire on October 25, 2004.

(4) Of these shares, 18,000 underlie options granted on September 12, 2000 to
    replace a like number of options previously granted to Mr. Glassman, which
    expired by their terms.  These options are exercisable after September 12,
    2001, 2002, 2003 for 6,000, 6,000 and 6,000 shares, respectively, at an
    exercise price of $1.41 per share, 110% of the fair market value for shares
    of common stock on the date of the grant.  These options will expire on
    September 11, 2005.  The remaining 341,589 shares underlie options granted
    on December 15,2000 to replace like number of options previously granted
    to Mr. Glassman, which expired by their terms.  These options are
    exercisable immediately at an exercise price of $1.44 per share, 110% of
    the fair market value for shares of common stock on the date of grant.
    These options will expire on December 4, 2005.

(5) These options are exercisable after September 6, 2000, 2001, 2002 for
    4,000, 4,000 and 4,000 shares, respectively, at an exercise price of $1.09
    per share, the fair market value for shares of common stock on the date of
    the grant.  These options will expire on September 6, 2009.



                            Option Grants in 2000
                            ---------------------


     The following table sets forth information concerning outstanding options
to purchase shares of our common stock granted by us to our Directors and
Officers during 2000. Neither options to purchase shares of Class B common stock
nor stock appreciation rights were granted by us during 2000.  The exercise
prices for all options reported below are not less than 100% of the per share
market prices for common stock on their dates of grant.


                                                      Individual Grants
                                                      -----------------
                                                      % of Total Options
                             Number of Securities         Granted To
                             Underlying Options            Employees
Name                              Granted                  in 2000(1)
----                              -------                  ----------


Daniel Glassman                   18,000                      3.95%
                                 341,589                     74.98%
Bradley Glassman                  18,000                      3.95%
Richard Fuisz                     30,000                      6.58%
Bruce Simpson                     15,000                      3.29%




                                 Exercise or
                                   Base
                                 Price ($/Sh)        Expiration Date
                                 ------------        ---------------

Daniel Glassman                     1.41                 09/11/05
                                    1.44                 12/04/05
Bradley Glassman                    1.38                 12/01/10
Richard Fuisz                       3.06                 04/29/01
Bruce Simpson                       1.97                 01/19/10



                   Aggregated Option Exercises in 2000
                       And Year-End Option Values
                       --------------------------


     The following table presents the value, on an aggregate basis, as of
December 31, 2000, of outstanding stock options held by our executive officers
listed in the Summary Compensation Table above.  No stock options were exercised
by the executive officers listed below during 2000.




                             Number of Securities         Value of Unexercised
                                  Underlying                  In-the-Money
                             Unexercised Options at             Options
                                   Year-End                    Year-End(1)
                                   --------                    -----------

Name                     Exercisable   Unexercisable  Exercisable  Unexercisable
----                     -----------   -------------  -----------  -------------

Daniel Glassman            569,755        176,334       $58,438      $116,875
Dileep Bhagwat               4,000          8,000        $4,375        $8,750
Robert Dubin                19,000          2,000        $7,500          -0-
Gene L. Goldberg            48,446           -0-        $20,702          -0-


(1) Based on the closing sale price of $1.406 per share of common stock on
    December 31, 2000, as reported by NASDAQ.

                            Employment Contracts and
         Termination of Employment and Change-in-Control Arrangements
         ------------------------------------------------------------


     We do not have any employment contracts or termination of employment or
change-in-control arrangements with any of our executive officers.


                            Compensation of Directors
                            -------------------------


     Directors who are not officers or employees receive a director's fee of
$750 for each meeting of the Board of Directors, or a committee thereof,
attended by such director, plus out-of-pocket costs.  Directors who are also
officers or employees receive no additional compensation for their services as
directors.

Item 11. Security Ownership of Certain Beneficial Owners and Management

     The following table sets forth certain information as of December 31,
1999, regarding the ownership of our common stock and Class B common stock by
(i) each director, (ii) the executive officers named in the Summary Compensation
Table set forth elsewhere in this document, (iii) each beneficial owner of more
than five percent of common stock and Class B common stock known by us and (iv)
all directors and executive officers, as a group, and the percentage of
outstanding shares of common stock and Class B common stock beneficially held
by them on that date.

     Since each share of Class B common stock may be converted at any time by
the holder into one share of common stock, the beneficial ownership rules
promulgated under the Securities Exchange Act of 1934, as amended, require that
all shares common stock issuable upon the conversion of Class B common stock by
any stockholder be included in determining the number of shares and percentage
of common stock held by such stockholder.


                           Amount and Nature of
                           Beneficial Owner(1)(2)        Percent of Class(2)
                           ----------------------        -------------------
Name and Address of                      Class B                       Class B
Beneficial Owner         Common Stock  Common Stock   Common Stock  Common Stock
----------------         ------------  ------------   ------------  ------------


Daniel Glassman           973,141(3)    363,946(4)       11.86%        84.33%
383 Route 46 West
Fairfield, NJ

Iris S. Glassman          226,003(5)     16,403(6)        2.75%         3.8%
383 Route 46 West
Fairfield, NJ

Philip McGinn, Jr.         20,972          -0-              *            -
383 Route 46 West
Fairfield, NJ

Alan G. Wolin              83,441(8)       -0-              *            -
383 Route 46 West
Fairfield, NJ

Seymour Schlager           10,000(12)      -0-              *            -
383 Route 46 West
Fairfield, NJ

Dileep Bhagwat              5,000(11)      -0-              *            -
383 Route 46 West
Fairfield, NJ

Robert Corbo               13,807(14)      -0-              *            -
383 Route 46 West
Fairfield, NJ

Robert Dubin               21,769(10)      -0-              *            -
383 Route 46 West
Fairfield, NJ

Brad Glassman              70,926(7)     20,880             *            -
383 Route 46 West
Fairfield, NJ

Gene L. Goldberg           62,457(9)     10,192             *            -
383 Route 46 West
Fairfield, NJ

R. Brent Lenczycki         12,509(13)      -0-              *            -
383 Route 46 West
Fairfield, NJ

Berlex Laboratories, Inc. 2,200,000(15)    -0-            26.81%         -
340 Changebridge Road
Montville, NJ  07045

All executive officers    1,500,025      411,421(4)(6)    18.28%       95.34%
and Directors as a       (3)(5)(7)(8)
group (9 Persons)      (9)(10)(11)(12)
                          (13)(14)


* Represents less than one
  percent



(1) Unless otherwise indicated, the stockholders identified in this table have
    sole voting and investment power with respect to the shares beneficially
    owned by them.

(2) Each named person and all executive officers and directors, as a group, are
    deemed to be the beneficial owners of securities that may be acquired
    within 60 days through the exercise of options, warrants or exchange or
    conversion rights.  Accordingly, the number of shares and percentage set
    forth opposite each stockholder's name under the columns Common Stock
    includes shares of common stock issuable upon exercise of presently
    exercisable warrants and stock options and shares of common stock issuable
    upon conversion of shares of Class B common stock.  The shares of common
    stock so issuable upon such exercise, exchange or conversion by any such
    stockholder are not included in calculating the number of shares or
    percentage of common stock beneficially owned by any other stockholder.

(3) Includes 363,946 shares issuable upon conversion of a like number of shares
    of Class B common stock.  Of these shares, 86,548 shares are owned
    indirectly by Mr. Glassman through affiliates and 519,755 shares underlie
    presently exercisable options owned by Mr. Glassman.  Mr. Glassman's
    affiliates have disclaimed beneficial ownership over all of these shares.
    Mr. Glassman disclaims beneficial ownership over shares and options owned
    by his spouse, Iris S. Glassman.

(4) Includes 25,736 shares owned indirectly by Mr. Glassman through affiliates.
    Mr. Glassman's affiliates have disclaimed beneficial ownership over these
    shares.  Does not include 16,403 shares beneficially owned by Iris S.
    Glassman, 	Mr. Glassman's spouse.

(5) Includes 16,403 shares issuable upon conversion of a like number of shares
    of Class B common stock, 6,800 shares owned indirectly by Mrs. Glassman
    through affiliates, 33,130 shares owned indirectly by Mrs. Glassman as
    trustee for her children's trusts and 168,070 shares underlying presently
    exercisable options.  Mrs. Glassman disclaims beneficial ownership over
    all shares beneficially owned by her husband, Daniel Glassman.

(6) Mrs. Glassman disclaims beneficial ownership over all shares of Class B
    common stock beneficially owned by her spouse, Daniel Glassman.

(7) Includes 20,880 shares issuable upon conversion of a like number of shares
    of Class B common stock held in trust for his benefit.  Includes 9,000
    shares underlying presently exercisable options.

(8) Includes 16,800 shares underlying presently exercisable options.

(9) Includes 10,192 shares issuable upon conversion of a like number of shares
    of Class B common stock.  Of these shares 48,446 shares underlie presently
    exercisable options.

(10) 2,769 shares are owned indirectly as trustee for Mr. Dubin's children and
     by his spouse.  Includes 19,000 shares underlying presently exercisable
     options.

(11) Includes 4,000 shares underlying presently exercisable options.

(12) Includes 10,000 shares underlying presently exercisable options.

(13) Includes 4,000 shares underlying presently exercisable options.

(14) Includes 6,800 shares underlying presently exercisable options.

(15) Includes 1,450,000 shares of common stock and 750,000 shares underlying
     presently exercisable warrants.


Item 12. Certain Relationships and Related Transactions

     During the years ended December 31, 2000 and 1999, we received
administrative support services (consisting principally of advertising services,
mailing, copying, financial services, data processing and other office services)
which were charged to operations from Banyan Communications Group, Inc.
("Banyan"), an affiliate, in the amount of  $215,190 and $197,800, respectively.

     We lease office facilities in Fairfield, New Jersey from Daniel and Iris
S. Glassman, directors and shareholders.  The lease is for the period from
February 1, 1998 to January 31, 2003 for 14,100 square feet of office and
warehouse space.  The rent expense, including an allocated portion of real
estate taxes, was approximately $225,000 and $224,000 for the years ended
December 31, 2000 and 1999, respectively.

     On January 3, 2000, we advanced $100,000 to Daniel Glassman, pursuant to
a promissory note bearing interest at 8.25% per annum.  The accrued interest
and principal is due in full, three years from the execution date, except that
fifty percent of all future bonus payments will be applied first to accrued
interest, then to principal.


Item 13. Exhibits, List and Reports on Form 8-K


     (a)     Reports on Form 8-K

             None filed in the Fourth Quarter.

     (b)     Exhibits


Exhibit
Number                           Description of Document
------                           -----------------------


3.1           Certificate of Incorporation of the Company, as amended
              (Incorporated by reference from the Company's Proxy Statement
              for the 1998 Annual Meeting)

3.2           By-laws of the Registrant, as amended (Incorporated by reference
              from the Company's Proxy Statement for the 1998 Annual Meeting)

4.1           Placement Agent's Unit Purchase Option (Incorporated by reference
              from the Company's Proxy Statement for the 1998 Annual Meeting)

10.1          1990 Stock Option Plan, as amended (Incorporated by reference to
              Exhibit 10.1 to the Company's Annual Report on Form 10-KSB for
              the year ended December 31, 1996

10.24         Amendment No. 6 to Asset Purchase Agreement, dated as of September
              19, 1997, between the Company and Berlex (Incorporated by
              reference to Exhibit 10.24 from the Company's Form SB-2 filed with
              Securities and Exchange Commission on October 15, 1997)

10.25         Warrant to Purchase up to 750,000 Shares of Common Stock of the
              Company issued to Berlex (Incorporated by reference to Exhibit
              10.25 from the Company's Form SB-2 filed with Securities and
              Exchange Commission on October 15, 1997)

21.1          Subsidiaries of the Registrant (Incorporated by reference to
              Exhibit 21.1 to the Company's Annual Report on Form 10-KSB for
              the year ended December 31, 1996)

23.2          Consent of Independent Certified Public Accountants

24.1          Power of Attorney (see page II-5)

27            Financial Data Schedule





                                SIGNATURES


     Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.


                      BRADLEY PHARMACEUTICALS, INC.



                      By/s/ Daniel Glassman
                      -----------------------------
                      Daniel Glassman
                      Chairman of the Board


     Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant in the capacities and on the dates indicated.


DATE                     SIGNATURE                          TITLE


March 29, 2001       /s/Daniel Glassman             Chairman of the Board
                     ------------------------       President and Chief
                     (Daniel Glassman)              Executive Officer
                                                   (Principal Executive Officer)


March 29, 2001       /s/Iris S. Glassman            Treasurer and Director
                     ------------------------
                     (Iris S. Glassman)


March 29, 2001       /s/Philip W. McGinn, Jr.       Director
                     ------------------------
                     (Dr. Philip W. McGinn, Jr.)


March 29, 2001       /s/Seymour I. Schlager         Director
                     ------------------------
                     (Dr. Seymour I. Schlager)


March 29, 2001       /s/Bruce W. Simpson            Secretary and Director
                     ------------------------
                     (Bruce W. Simpson)


March 29, 2001       /s/Alan G. Wolin               Director
                     ------------------------
                     (Dr. Alan Wolin)